UNCY
Unicycive Therapeutics, Inc. · Healthcare
6.63
0.30%(−0.02)
Close PriceLast Updated: — ET
52W L: $3.7152W H: $11.00
Unicycive Therapeutics, Inc. · Healthcare
Aggarwal Gaurav
director
652,900 SH @ $0.00
2025-08-25
Aggarwal Gaurav
director
3,199.21 SH @ $4.90
2025-08-25
Aggarwal Gaurav
director
21,200 SH @ $4.71
2025-07-28
Laumas Sandeep
director
21,200 SH @ $4.71
2025-07-28
Kenkare-Mitra Sara
director
21,200 SH @ $4.71
2025-07-28
Gupta Shalabh K.
director, officer: CEO
325,000 SH @ $4.71
2025-07-28
Townsend John
officer: Chief Financial Officer
10,000 SH @ $4.71
2025-07-28
Gupta Pramod
officer: EVP, Pharmaceuticals and BD
90,000 SH @ $4.71
2025-07-28
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.
LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update.
Unicycive Therapeutics, Inc. (NASDAQ: UNCY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokers
New York, New York--(Newsfile Corp. - March 6, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.
Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).